• Faron Pharmaceuticals flagged changes across its investigator-initiated trial portfolio for bexmarilimab, including one program setback.
• Finnish regulator Fimea ruled the proposed bexmarilimab cohort incompatible with the FINPROVE precision-medicine platform trial, stopping that cohort.
• BLAZE switched its anti-PD-1 backbone to nivolumab, clearing approvals and moving toward first patient enrollment in PD-1–resistant NSCLC or melanoma.
• BEXAR in first-line metastatic soft-tissue sarcoma also secured regulatory and ethics clearances, moving toward initial recruitment.
• Two additional hematology studies remain in protocol development and regulatory submission preparation, including AML post-transplant MRD-positive and relapsed or refractory MDS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.